NeuroMetrix, Inc. (NURO)

Market Cap	8.82M
Revenue (ttm)	5.90M
Net Income (ttm)	-6.53M
Shares Out	1.99M
EPS (ttm)	-6.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,298
Open	4.330
Previous Close	4.410
Day's Range	4.300 - 4.640
52-Week Range	2.700 - 11.520
Beta	2.32
Analysts	n/a
Price Target	n/a
Earnings Date	May 10, 2024

About NURO

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disp...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1996
• Employees: 26
• Stock Exchange: NASDAQ
• Ticker Symbol: NURO

Financial Performance

In 2023, NeuroMetrix's revenue was $5.90 million, a decrease of -28.52% compared to the previous year's $8.26 million. Losses were -$6.53 million, 47.8% more than in 2022.